Skip to main content
Midas Edge

Prime Medicine, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

PRME$3.90-9.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders Equity for the

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Common Stock · AdditionalPaid-inCapital · Accumulated OtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity
(in thousands, except share amounts) · Shares · Amount
Balance as of December 31, 2025180,514,014$2$1,009,138$82$(888,354)$120,868
Issuance of common stock upon exercise of stock options101,500—393——393
Stock-based compensation expense——4,644——4,644
Change in unrealized income (loss) on investments, net of tax———(83)—(83)
Net loss————(49,122)(49,122)
Balance as of March 31, 2026180,615,514$2$1,014,175$(1)$(937,476)$76,700

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Common Stock · AdditionalPaid-inCapital · Accumulated OtherComprehensiveIncome (Loss) · AccumulatedDeficit · TotalStockholders’Equity
(in thousands, except share amounts) · Shares · Amount
Balance as of December 31, 2024131,160,842$2$840,358$1$(687,212)$153,149
Stock-based compensation expense——5,681——5,681
Change in unrealized income (loss) on investments, net of tax———(16)—(16)
Net loss————(51,890)(51,890)
Balance as of March 31, 2025131,160,842$2$846,039$(15)$(739,102)$106,924
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.